Cargando…
Hypernatremia induced by low-dose Tolvaptan in a Patient with refractory heart failure: A case report
RATIONALE: Tolvaptan (TLV) is a selective vasopressin type 2 receptor antagonist, which has an active effect on patients with congestive heart failure especially combined with hyponatremia. Increasingly, evidence has demonstrated that low-dose tolvaptan can dramatically relieve patients’ dyspnea and...
Autores principales: | Li, Tian, Li, Gui-Shuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635281/ https://www.ncbi.nlm.nih.gov/pubmed/31277136 http://dx.doi.org/10.1097/MD.0000000000016229 |
Ejemplares similares
-
Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure
por: Fukuoka, Hidetada, et al.
Publicado: (2020) -
Post-hepatectomy tolvaptan-induced hypernatremia in a hepatocellular carcinoma patient with cirrhosis: a case report
por: Iida, Hiroya, et al.
Publicado: (2020) -
Long-Term Tolvaptan Treatment in Refractory Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2019) -
Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia
por: Oka, Tatsufumi, et al.
Publicado: (2021) -
Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)